Ipsen Pharmaceuticals

illustration of two arrows going in opposite directions
Biotech

Ipsen hands back Sutro's ROR1 ADC at center of $875M deal

Ipsen has backed out of a $900 million biobucks deal for Sutro Biopharma’s ROR1-directed antibody-drug conjugate.
James Waldron Aug 8, 2025 6:15am
image of two race cars neck and neck

Ipsen joins ADC race via $900M biobuck deal with Sutro

Apr 2, 2024 7:26am
apoptosis cell death cancer cell death

Cell death biotech folds in 'challenging funding environment'

Jul 11, 2023 4:00am
parachute sunset paragliding chutes

BMS CEO set to leave after 8-year run—Chutes & Ladders

Apr 28, 2023 9:30am
FDA

FDA agrees to give Ipsen's rare disease drug another look

Mar 17, 2023 7:12am
Abstract image of a human brain-stock image Khanchit KhirisutchalualGetty Images

Irlab's Ipsen-partnered Parkinson's drug flunks phase 2 trial

Jan 18, 2023 10:08am